OREANDA-NEWS. PSI CRO, a global full-service contract research organization, announced today that PSI has taken top honors among global CROs in the bi-annual CenterWatch Global Investigator Site Survey report. The survey results were published April 1, 2015 by CenterWatch and PSI was ranked as the top CRO for investigative site relationships.

PSI is very pleased about the CenterWatch results as it validates the hard work and dedication their operational staff are putting into working with the sites around the world.

CenterWatch’s 2015 Global Investigator Site Survey was conducted online from October 2014 to January 2015 and asked principal investigators, sub-investigators and study coordinators to rate the CROs with which they worked during the past two years on 37 project attributes. More than 72% of the 1,900 responders were from North America and Europe. The top five attributes that were considered the most important for the survey which resulted in number One ranking for PSI was a) how professional, knowledgeable and well trained are monitors/CRAs, b) how well organized and prepared are the CRO staff, c) timely drug delivery availability, d) professional medical staff in clinical operations, e) professional staff for escalation of issues and provides timely and appropriate resolution.

The CRA is on the frontline of site communication. How well PSI approaches hiring and training of CRAs will largely determine the success of the relationship we manage to have with the site. PSI invests into MD hires among CRAs and runs robust training programs. Keeping turnover of CRAs low is critical to a long-term success with the sites. (At PSI, CRA turnover company-wide is only 3%). PSI systems are set up to support the sites with everything they may need, while, at the same time, create an environment of mutual accountability. We have faith in teamwork. When the biggest fear between the two is not to let the other down, things begin to shift.

PSI’s Olga Alfonsova stated: “We would like to think that PSI is giving our customers better service with each new clinical trial program. For us this means to reliably enroll larger, more complex studies on or ahead of schedule across more continents with consistently high data quality. Repeat business is generally a great indicator of how effective you are. At PSI, we measure ourselves against the willingness of our sponsors, sites and, importantly, our own employees to work with PSI on the next project”.